Movantik (Naloxegol Oxalate) Patent Expiration, LOE Window & CMS Spending

Movantik (Naloxegol Oxalate) by Averitas: FDA Orange Book core substance LOE 2032-04-02, 0 AB generics, $176.1M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAveritas
FDA Application & PathwayN204760 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2032-04-02
Last Listed Patent or Exclusivity Date2032-04-02
Orange Book Patents (*PED Extensions)2 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$176.1M
2024 Medicare Part D Spend$153.3M
2024 Medicaid Spend$22.8M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel